Sacituzumab govitecan response in extensive leptomeningeal carcinomatosis from triple-negative breast cancer: a case report

Sacituzumab govitecan response in extensive leptomeningeal carcinomatosis from triple-negative breast cancer: a case report

Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate (ADC), was the first ADC approved for patients with metastatic triple-negative breast cancer (mTNBC) who had received at least two prior lines of therapy for advanced disease. Although SG has shown promising clinical activity in t...

Full description

Bibliographic Details
Main Authors: Jesús Yaringaño, María Roca-Herrera, Simeón Eremiev, Pau Mascaró-Baselga, Pau Benito, Fidel Núñez, Sergi Benavente, Isabel Pimentel
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-08-01
Series:Frontiers in Oncology
Subjects:
triple-negative breast cancer
leptomeningeal carcinomatosis
antibody-drug conjugate
sacituzumab govitecan
partial response
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1378248/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1378248/full

Similar Items